A powerful wave of new therapies is reshaping how doctors treat acute myeloid leukemia (AML) in older adults. The updated 2025 American Society of Hematology (ASH) guidelines, led by Dr. Mikkael Sekeres of the University of Miami’s Sylvester Comprehensive Cancer Center, highlight this progress. The recommendations appear in Blood Advances and will be discussed at the ASH Annual Meeting on December 7 in Orlando.
More Effective Therapies Now Within Reach
Researchers have introduced several targeted drugs and improved chemotherapy options in recent years. These treatments now deliver stronger responses and better survival rates. Dr. Sekeres and his team supported the FDA approval of three leukemia medications in the past two years. This marks a major step forward for patients who once had very limited choices.
Guidelines Built on Real Patient Discussions
The updated AML guidelines reflect input from leukemia specialists, geriatricians, and patient advocates. Their goal was clear: create recommendations that match real conversations with older adults. Many patients first ask whether they should pursue treatment at all. That question carried much more uncertainty in the past, especially for people over age 65.
From Limited Options to Personalized Therapy
Twenty years ago, most older adults never received chemotherapy. Today, most can safely begin treatment and reach remission. AML care now relies on individualized planning. Doctors consider age, overall health, and genetic features before selecting therapy. This approach helps clinicians choose the safest and most effective strategy for each patient.
Modern Therapies Tailored to Each Patient
Many fit older adults, especially those in their 60s or with favorable genetics, may still benefit from intensive chemotherapy. Others respond very well to lower-intensity options such as azacitidine, decitabine, or low-dose cytarabine. These regimens work even better when combined with venetoclax, a widely used targeted drug.
Genetic testing now guides many treatment choices. Patients with FLT3 mutations often receive FLT3 inhibitors. Those with IDH1 or IDH2 mutations benefit from combinations that include agents like ivosidenib or venetoclax. This precision-medicine model helps doctors match each therapy to the leukemia’s biological behavior.
Transplant Options Expanding for Older Adults
More older adults can now consider bone marrow transplantation after remission. Improved donor matching and safer transplant methods open this option to patients who previously had no access to it. For individuals who cannot undergo transplant, the guidelines recommend maintenance therapy to reduce relapse risk.
Updated Standards for Palliative Care
The new ASH guidelines also strengthen recommendations for end-of-life care. Many hospices once declined transfusions for leukemia patients, even when transfusions provided comfort. The updated guidance states that transfusions should remain a standard part of palliative and hospice care for AML.
Better Diagnostic Tools, Better Outcomes
Researchers now use advanced techniques to detect minimal residual disease, the small number of remaining leukemia cells after treatment. These tools help doctors predict relapse and identify who may benefit most from a transplant. As Dr. Justin Watts explains, these improvements steadily increase the number of patients who reach favorable outcomes.
A Future Filled With More Hope
The 2025 AML guidelines show how far leukemia care has advanced. Older adults now benefit from safer therapies, stronger targeted drugs, and broader transplant opportunities. As research moves forward, more patients can access treatment plans that feel personalized, compassionate, and better prepared to deliver long-term survival.
About The Author
